Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous...
April 07 2021 - 4:05PM
Business Wire
Presenters include Dr. Amir Azadi of Barrow
Neurological Institute, Dr. Nicholas Blondin of Yale University and
Dr. Priya U. Kumthekar of Northwestern University
Webinar begins tomorrow, April 8, at 12:00 p.m.
Eastern Time
Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring
leading neuro-oncologists to discuss the use of the Company’s
proprietary cerebrospinal fluid (CSF) assay for diagnosing and
managing tumors that have metastasized to the central nervous
system (CNS), including the brain or spinal column. Biocept’s CSF
assay provides enhanced sensitivity compared with CSF cytology, the
current standard of care, and has the added advantage of
identifying actionable molecular targets for use in treatment
decisions while providing quantitative information needed for
assessing treatment response and monitoring disease
progression.
Webinar Details
Date: Thursday, April 8, 2021 Time: 12:00 p.m.
Eastern time (9:00 a.m. Pacific time) Registration:
Participants can pre-register or register at webinar start time
here.
The webinar also will be available live and archived at
www.biocept.com.
Amir Azadi, MD is a medical oncologist specializing in
neuro-oncology and an Assistant Professor in the Department of
Neurology at Barrow Neurological Institute. His expertise includes
the diagnosis and treatment of brain tumors. He is board certified
in internal medicine and medical oncology by the American Board of
Internal Medicine, and is a member of the American College of
Physicians, the American Society of Clinical Oncology, the Society
for Immunotherapy of Cancer and the Society of Neuro-Oncology. Dr.
Azadi received his medical degree from Shahid Beheshti University
of Medical Sciences in Tehran, Iran. He completed his residency in
internal medicine at Banner – University Medical Center in Phoenix,
and fellowships in hematology and oncology at the University of
Louisville James Graham Brown Cancer Center and in neuro-oncology
at Barrow Neurological Institute.
Nicholas Blondin, MD is Assistant Professor of Clinical
Neurology at Yale School of Medicine. His clinical expertise is in
treating benign and malignant brain tumors, brain and spine
metastasis, and neurological symptoms of cancer such as seizures,
cognitive impairment, headaches, gait disturbance and weakness. Dr.
Blondin is an active investigator for clinical trials for brain
tumor patients through Yale Cancer Center. He received his Medical
Degree from the University of Connecticut School of Medicine and
completed his neurology residency at Yale New Haven Hospital, where
he was Chief Resident in Neurology, followed by a fellowship in
neuro-oncology at Yale New Haven Hospital.
Priya U. Kumthekar, MD is a United Counsel for Neurologic
Subspecialties (UCNS)-certified neuro-oncologist from Northwestern
University and is serving as the principal investigator for
Biocept’s Four C clinical study. She is dedicated to patient care
and moving the study of brain tumors forward primarily through her
leadership on clinical trials. Dr. Kumthekar serves in leadership
roles with the National Clinical Trials Network, particularly with
the Alliance for Clinical Trials, and was named as the Alliance’s
national Executive Officer of Neuro-Oncology in 2016. In this role,
she oversees the conception and development of clinical trials from
early phase through registration studies. Dr. Kumthekar is board
certified in neurology and is a member of the American Board of
Psychiatry and Neurology. She received her medical degree from
Northeastern Ohio University. She previously was Chief Resident at
Northwestern University, McGaw Medical Center.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept is developing and
commercializing its cerebrospinal fluid (CSF) assay that detects
cancer that has metastasized to the central nervous system. The
Company’s CSF assay identifies molecular targets for clinical
decision making and provides quantitative information for
monitoring treatment response. Biocept’s patented Target Selector™
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and
circulating tumor DNA (ctDNA) with higher sensitivity and
specificity than most commercial assays. Additionally, Biocept is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For additional information,
visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210407005354/en/
Investor Contact LHA
Investor Relations Jody Cain Jcain@lhai.com, (310) 691-7100
Media Contact Sampson PR
Group Andrea Sampson asampson@sampsonprgroup.com, (562)
304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024